Mediwound Ltd (MDWD)

[midastouch017]

EMA Provides Regulatory Path for Pediatric Label Extension for NexoBrid

https://finance.yahoo.com/news/ema-provides-regulatory-path-pediatric-123000141.html

Anticipate Submission for Label Extension in First Half 2022

YAVNE, Israel, Nov. 18, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that the Company has received positive scientific advice from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) related to the pediatric label extension for NexoBrid. Based on the feedback, the Company anticipates submitting a pediatric label extension request in the first half of 2022.

EMA’s CHMP agreed to assess a potential pediatric label extension on NexoBrid for the treatment of thermal burns, based on the available safety and efficacy results of the pivotal phase 3 pediatric clinical study (CIDS – Children Innovation Debridement Study) with its 12-month follow-up, and that the long-term follow up data are likely to be supportive data.

“We are very pleased to have received support and positive guidance from the CHMP on the regulatory pathway towards a pediatric label extension for NexoBrid,” said Sharon Malka, Chief Executive Officer of MediWound. “Having a non-surgical option for these severely burned young patients will be a significant step forward over the current surgical standard of care, which involves painful surgery with long recovery times. NexoBrid growth in Europe has been strong, and with the potential pediatric label extension, our commercial team and distribution partners are looking forward to expanding the market and continuing to improve on the standard of care.”

Summary of Phase 3 CIDS study

The study met its three primary endpoints with a high degree of statistical significance. NexoBrid demonstrated a significant reduction in time to achieve complete eschar removal and significant reduction in wound area requiring surgical excision (surgical need) while demonstrating non-inferiority to SOC in quality of scars. The study also met certain secondary endpoints showing statistically significant reduction in the incidence of surgical excision and reduction in need for autograft in deep partial burns, as well as a favorable trend in reduction of blood loss during the eschar removal process. In addition, the study showed that NexoBrid was safe and well-tolerated.

Funding and support for this pivotal pediatric Phase 3 clinical study (CIDS) with NexoBrid is provided by the Biomedical Advanced Research and Development Authority (BARDA), under the office of the Assistant Secretary for Preparedness and Response (ASPR), within the U.S. Department of Health and Human Services (HHS), under ongoing contract number HHSO100201500035C.